Click here to view a PDF of Therion's corporate fact sheet Therion Biologics Corporation develops therapeutic vaccines for cancer and preventive vaccines for AIDS. The Company has two lead programs involving multiple clinical studies: PANVAC-VF™ for pancreatic cancer and PROSTVAC-VF® for prostate cancer. Therion is also applying its technology platform to develop vaccines to treat melanoma, breast cancer and other solid tumors. In addition to studies conducted under collaboration with the National Cancer Institute, the Company�s strategic partners include a global network of leading clinical institutions and Aventis Pasteur, Ltd., which is developing ALVAC-CEA/B7.1, a clinical candidate for the treatment of colon cancer. Therion is headquartered in Cambridge, Massachusetts. Therion's goal is to generate safe and effective therapies that stimulate the immune system to specifically attack cancer cells, and thereby stabilize disease or induce tumor regression, improve patients' quality of life, and increase patient survival. Therion is also developing a preventative vaccine for AIDS under grants and contracts with the National Institutes of Health and with the International AIDS Vaccine Initiative (IAVI). Management Team Board of Directors Scientific Adv. Board Investors Contact Us Therion�s Approach to Treating Cancer Recent advancements in immunology and tumor biology have provided a better understanding of the key molecular signals involved in eliciting potent and specific immune responses, and have led to the development of a new generation of therapeutic cancer treatments. Therion is at the forefront of cancer immunotherapy. Therion has developed a powerful technology, based on its proprietary antigen delivery system, that allows simultaneous in vivo expression of key components.  Preclinical studies indicate this technology can stimulate and sustain potent and specific immune responses against cancer cells. The Company's unique development approach enables rapid generation and clinical evaluation of multiple product candidates for a variety of disease indications. To date, Therion�s vaccine candidates have been evaluated in over 30 clinical trials and in more than 700 patients. Capitalizing on recent scientific progress, Therion is targeting many of the major cancers currently lacking adequate treatment. Therion's therapeutic cancer vaccine candidates for prostate, pancreatic, breast, colorectal cancers, as well as melanoma, address a majority of the large and rapidly growing markets for cancer treatments. Back to the top Copyright © Therion Biologics Corporation.